A detailed history of Advantage Alpha Capital Partners LP transactions in Adma Biologics, Inc. stock. As of the latest transaction made, Advantage Alpha Capital Partners LP holds 69,182 shares of ADMA stock, worth $1.07 Million. This represents 0.31% of its overall portfolio holdings.

Number of Shares
69,182
Previous 87,391 20.84%
Holding current value
$1.07 Million
Previous $1.75 Million 32.07%
% of portfolio
0.31%
Previous 0.42%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2024

Feb 11, 2025

SELL
$15.62 - $22.62 $284,424 - $411,887
-18,209 Reduced 20.84%
69,182 $1.19 Million
Q3 2024

Nov 13, 2024

SELL
$11.21 - $20.03 $741,653 - $1.33 Million
-66,160 Reduced 43.09%
87,391 $1.75 Million
Q2 2024

Aug 13, 2024

SELL
$5.98 - $11.18 $184,871 - $345,629
-30,915 Reduced 16.76%
153,551 $1.72 Million
Q1 2024

May 13, 2024

BUY
$4.4 - $6.74 $811,650 - $1.24 Million
184,466 New
184,466 $1.22 Million

Others Institutions Holding ADMA

About ADMA BIOLOGICS, INC.


  • Ticker ADMA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 196,356,992
  • Market Cap $3.05B
  • Description
  • ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. It offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primar...
More about ADMA
Track This Portfolio

Track Advantage Alpha Capital Partners LP Portfolio

Follow Advantage Alpha Capital Partners LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Advantage Alpha Capital Partners LP, based on Form 13F filings with the SEC.

News

Stay updated on Advantage Alpha Capital Partners LP with notifications on news.